Di Silvio resigns as Pyng CEO
This article was originally published in Clinica
Executive Summary
Robert Di Silvio has resigned as president and CEO of emergency trauma care and resuscitation firm Pyng Medical. His resignation is effective as of 30 September, after which he will join an unnamed medical company based in the San Francisco Bay area. Mr Di Silvio will remain as a member of Pyng’s board of directors. Mark Hodge will become Pyng’s interim president and CEO on 1 October, a role he is expected to hold for six months. Mr Hodge is a management consultant that has been working with Pyng since June 2009. He previously worked for Medtronic and Boston Scientific in a marketing, operations and engineering capacity.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals